Iminoribitol transition state analogue inhibitors of protozoan nucleoside hydrolases.
Nucleoside N-ribohydrolases from protozoan parasites are targets for inhibitor design in these purine-auxotrophic organisms. Purine-specific and purine/pyrimidine-nonspecific nucleoside hydrolases have been reported. Iminoribitols that are 1-substituted with meta- and para-derivatized phenyl groups [(1S)-substituted 1, 4-dideoxy-1,4-imino-D-ribitols] are powerful inhibitors for the nonspecific nucleoside N-ribohydrolases, but are weak inhibitiors for purine-specific isozymes [Parkin, D. W., Limberg, G., Tyler, P. C., Furneaux, R. H., Chen, X.-Y., and Schramm, V. L. (1997) Biochemisty 36, 3528-3534]. Binding of these inhibitors to nonspecific nucleoside hydrolase occurs primarily via interaction with the iminoribitol, a ribooxocarbenium ion analogue of the transition state. Weaker interactions arise from hydrophobic interactions between the phenyl group and the purine/pyrimidine site. In contrast, the purine-specific enzymes obtain equal catalytic potential from leaving group activation and ribooxocarbenium ion formation. Knowledge of the reaction mechanisms and transition states for these enzymes has guided the design of isozyme-specific transition state analogue inhibitors. New synthetic efforts have produced novel inhibitors that incorporate features of the leaving group hydrogen-bonding sites while retaining the iminoribitol group. These compounds provide the first transition state analogue inhibitors for purine-specific nucleoside hydrolase. The most inhibitory 1-substituted iminoribitol heterocycle is a sub-nanomolar inhibitor for the purine-specific nucleoside hydrolase from Trypanosoma brucei brucei. Novel nanomolar inhibitors are also described for the nonspecific nucleoside hydrolase from Crithidia fasciculata. The compounds reported here are the most powerful iminoribitol inhibitors yet described for the nucleoside hydrolases.
Miles
R W
RW
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Tyler
P C
PC
Evans
G B
GB
Furneaux
R H
RH
Parkin
D W
DW
Schramm
V L
VL
D000818:Animals; D016831:Crithidia fasciculata / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000737:chemistry*; D006151:Guanosine / Q000737:chemistry; D006860:Hydrogen Bonding; D007288:Inosine / Q000737:chemistry; D046911:Macromolecular Substances; D009699:N-Glycosyl Hydrolases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D015800:Protozoan Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry; D011687:Purines / Q000737:chemistry; D011744:Pyrimidinones / Q000737:chemistry; D011758:Pyrroles / Q000737:chemistry; D012255:Ribitol / Q000031:analogs & derivatives* / Q000737:chemistry; D012266:Ribose / Q000737:chemistry; D013329:Structure-Activity Relationship; D013379:Substrate Specificity
D004791:Enzyme Inhibitors; D046911:Macromolecular Substances; D015800:Protozoan Proteins; D011687:Purines; D011744:Pyrimidinones; D011758:Pyrroles; C089322:phenyliminoribitol; D006151:Guanosine; D012255:Ribitol; D007288:Inosine; D012266:Ribose; D009699:N-Glycosyl Hydrolases; C110539:inosine-adenosine-guanosine-preferring nucleoside hydrolase; C096466:inosine-uridine hydrolase